{"entity":{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","aka":[],"tldr":"Several studies found patients infused with checkpoint inhibitors earlier in the day lived longer. If a randomised trial confirms it, it is a free improvement available everywhere tomorrow.","summary":"This idea proposes giving immunotherapy in the morning: patients infused with checkpoint inhibitors earlier in the day lived longer in several studies, and a randomised trial could confirm a free improvement. Retrospective cohorts (Lancet Oncology 2021 and follow-ups) and the small randomised MEMOIR signal associate morning infusions with better survival, plausibly through circadian T-cell trafficking (Circadian control pathway). The hypothesis is that infusing Immune checkpoint inhibitors against PD-1 before midday improves overall survival compared with afternoon infusions, backed by consistent cohort data and mouse immunology. The test is a large pragmatic randomised trial of morning against afternoon infusion in first-line PD-1 therapy for Non-small-cell lung cancer and Melanoma.","asOf":"2026-09-08","links":[{"label":"Qian et al., Effect of immunotherapy time-of-day infusion on overall survival in advanced melanoma (Lancet Oncology 2021)","url":"https://doi.org/10.1016/S1470-2045(21)00546-5"}],"tags":["mechanism","open-question"],"related":[],"cancers":["nsclc","melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":[],"companies":[],"institutions":["mskcc","gustave-roussy"],"pathways":["circadian-control","pd1-checkpoint"],"terms":[],"trials":["checkmate-227","checkmate-915","fianlimab-phase3-melanoma","keynote-042","relativity-098"],"people":[],"bottlenecks":[],"keyPapers":["paper-qian-lancet-oncol","paper-topalian-anti-pd1-nejm-2012","paper-pd-1-nsclc-am-j-clin-oncol-2016","paper-kras-nsclc-cancer-discov-2018"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Scheduling checkpoint-inhibitor infusions before midday improves overall survival compared with afternoon infusions, with an effect size large enough to change infusion-unit scheduling.","rationale":"Consistent direction across cohorts, mechanistic backing in mouse immunology, zero drug cost, and trivial implementation.","test":"Large pragmatic randomised trial of morning vs afternoon infusion in first-line PD-1 therapy for NSCLC and melanoma, endpoint OS; embedded immune-trafficking biomarkers.","maturity":"early-clinical"},"route":"/ideas/idea-chronotherapy-immunotherapy/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"pathway":[{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"}],"trial":[{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/"},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/"},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/"},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/"},{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/"}],"paper":[{"id":"paper-pd-1-nsclc-am-j-clin-oncol-2016","kind":"paper","name":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","route":"/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/"},{"id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/"},{"id":"paper-kras-nsclc-cancer-discov-2018","kind":"paper","name":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","route":"/key-papers/paper-kras-nsclc-cancer-discov-2018/"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/"}],"idea":[{"id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/"}]}}